Edgewise Therapeutics
EWTXEdgewise Therapeutics, Inc. (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company based in the United States. The company's primary business focus is the discovery and development of oral, small molecule therapies designed to treat rare muscle disorders. Its research and development efforts are centered on targeting the fundamental biology of muscle tissue to address conditions characterized by muscle weakness and degeneration. The company's lead product candidate is EDG-5506, an oral small molecule designed to selectively limit excessive skeletal muscle contraction. This candidate is being investigated for the treatment of Becker muscular dystrophy, Duchenne muscular dystrophy, and other rare neuromuscular disorders. Edgewise Therapeutics is conducting multiple clinical trials to evaluate the safety, tolerability, and efficacy of EDG-5506 across these patient populations. As a publicly traded entity, Edgewise Therapeutics operates within the biotechnology sector with a specific concentration on muscle diseases. The company's pipeline and strategic direction are dedicated to advancing therapeutic options for disorders that currently have limited treatment modalities, with its clinical progress documented through public regulatory filings and scientific presentations.
EWTX · Stock Price
Historical price data
About
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company based in the United States. The company's primary business focus is the discovery and development of oral, small molecule therapies designed to treat rare muscle disorders. Its research and development efforts are centered on targeting the fundamental biology of muscle tissue to address conditions characterized by muscle weakness and degeneration. The company's lead product candidate is EDG-5506, an oral small molecule designed to selectively limit excessive skeletal muscle contraction. This candidate is being investigated for the treatment of Becker muscular dystrophy, Duchenne muscular dystrophy, and other rare neuromuscular disorders. Edgewise Therapeutics is conducting multiple clinical trials to evaluate the safety, tolerability, and efficacy of EDG-5506 across these patient populations. As a publicly traded entity, Edgewise Therapeutics operates within the biotechnology sector with a specific concentration on muscle diseases. The company's pipeline and strategic direction are dedicated to advancing therapeutic options for disorders that currently have limited treatment modalities, with its clinical progress documented through public regulatory filings and scientific presentations.